Source-grounded facts extracted from PRECISION BIOSCIENCES INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PRECISION BIOSCIENCES INC amended term loan of Term Loan under the Loan and Security Agreement with Banc of California at Existing interest rate (no change) maturing Extended from June 30, 2027 to December 31, 2029.
“The First Amendment extended the maturity date of the Term Loan (as defined in the Loan and Security Agreement) from June 30, 2027, to December 31, 2029.”
PRECISION BIOSCIENCES INC amended First Amendment to Amended and Restated Loan and Security Agreement with Banc of California (effective 2026-06-10).
“On June 10, 2026, Precision BioSciences, Inc. (the “Company”) and Banc of California (the “Lender”) entered into a First Amendment to Amended and Restated Loan and Security Agreement (the “First Amendment”).”
PRECISION BIOSCIENCES INC shareholders approved Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the other proposals. at the 2026-05-21 meeting.
“Item 6 – Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the other proposals. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 16,653,283 5,647,737 3,847 0”
PRECISION BIOSCIENCES INC shareholders approved Approval of an amendment to the Company’s Certificate of Incorporation to reflect changes in Delaware law regarding officer exculpation. at the 2026-05-21 meeting.
“Item 5 – Approval of an amendment to the Company’s Certificate of Incorporation to reflect changes in Delaware law regarding officer exculpation. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 17,909,703 1,411,694 6,136 2,977,334”
PRECISION BIOSCIENCES INC shareholders approved Approval of the amendment and restatement of the Company’s 2019 Incentive Award Plan. at the 2026-05-21 meeting.
“Item 4 – Approval of the amendment and restatement of the Company’s 2019 Incentive Award Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 11,170,635 8,145,992 10,906 2,977,334”
PRECISION BIOSCIENCES INC shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. at the 2026-05-21 meeting.
“Item 3 – Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 18,696,193 612,836 18,504 2,977,334”
PRECISION BIOSCIENCES INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. at the 2026-05-21 meeting.
“Item 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 22,198,597 99,879 6,391 0”
PRECISION BIOSCIENCES INC shareholders approved Election of two Class I directors to serve until the Company’s annual meeting of stockholders to be held in 2029 and until their respective successors have been duly elected and qualified. at the 2026-05-21 meeting.
“Item 1 – Election of two Class I directors to serve until the Company’s annual meeting of stockholders to be held in 2029 and until their respective successors have been duly elected and qualified. Votes FOR Votes WITHHELD Broker Non-Votes Melinda Brown 14,348,888 4,978,645 2,977,334 Geno Germano 14,288,270 5,039,263 2,977,334”
PRECISION BIOSCIENCES INC: Amended certificate of incorporation to provide for exculpation of certain officers as permitted by Delaware law (effective 2026-05-22).
“On May 22, 2026, the Company filed the 2026 Amendment with the Secretary of State of the State of Delaware, and the 2026 Amendment became effective upon filing.”
PRECISION BIOSCIENCES INC reported financial results for first quarter ended March 31, 2026.
“Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.”
PRECISION BIOSCIENCES INC reported financial results for the fourth quarter and fiscal year ended December 31, 2025.
“On March 12, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025.”
Sam Wadsworth resigned as Director at PRECISION BIOSCIENCES INC.
“On January 23, 2025, Sam Wadsworth, Ph.D., notified Precision BioSciences, Inc. (the “Company”) of his intention to retire from service on company boards and resigned from the Company’s Board of Directors.”
Alan List departed as Chief Medical Officer at PRECISION BIOSCIENCES INC.
“On September 9, 2024, Alan List, M.D., the Company’s Chief Medical Officer, notified Precision BioSciences, Inc. (the “Company”) that he will be retiring from the Company, effective September 13, 2024.”
PRECISION BIOSCIENCES INC terminated Amended and Restated Development and License Agreement with Prevail Therapeutics Inc. valued at Termination without cause upon 90 days notice (effective 2024-04-11).
“On April 11, 2024, Precision BioSciences, Inc. (the “Company”) received written notice from Prevail Therapeutics Inc. (“Prevail”), a wholly-owned subsidiary of Eli Lilly and Company, of Prevail’s termination of the Amended and Restated Development and License Agreement, dated June 30, 2023, between Prevail and the Company (the “Agreement”).”
PRECISION BIOSCIENCES INC reported financial results for quarter and fiscal year ended December 31, 2023.
“On March 27, 2024, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.”
PRECISION BIOSCIENCES INC: Amended certificate of incorporation to effect a 1-for-30 reverse stock split (effective 2024-02-13).
“On February 13, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment (the “Certificate of Amendment”) to amend the Certificate of Incorporation to effect the Reverse Stock Split.”
PRECISION BIOSCIENCES INC shareholders approved Approval of an adjournment of the Special Meeting, if necessary, to solicit additional proxies at the 2024-01-18 meeting.
“Proposal 2 – The approval of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal 1. Votes FOR Votes AGAINST Votes ABSTAINED BROKER NON-VOTES 75,291,080 7,698,338 339,229 0”
PRECISION BIOSCIENCES INC shareholders approved Approval of amendments to the company's amended and restated certificate of incorporation to effect a reverse stock split of the company's common stock at a ratio ranging from 1-for-10 to 1-for-30 at the 2024-01-18 meeting.
“Proposal 1 – The approval of amendments to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s Common Stock at a ratio ranging from any whole number between 1-for-10 and 1-for-30, as determined by the Company’s Board of Directors (the “Board”) in its discretion, subject to the Board’s authority to abandon such amendments. Votes FOR Votes AGAINST Votes ABSTAINED BROKER NON-VOTES 71,771,593 11,275,251 281,803 0”
PRECISION BIOSCIENCES INC entered into License Agreement with TG Cell Therapy, Inc. and TG Therapeutics, Inc. valued at upfront cash payment of $10.0 million (effective 2024-01-07).
“On January 7, 2024 (the “Effective Date”), Precision BioSciences, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with TG Cell Therapy, Inc. (“TG Subsidiary”) and its parent company TG Therapeutics, Inc. (“TG Parent” and, together with TG Subsidiary, “TG Therapeutics”), pursuant to which the Company granted TG Subsidiary certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize non-oncological applications of the Company’s allogeneic CAR T therapy azer-cel (collectively, the “Licensed Product”) pursuant to the terms of the License Agreement.”
PRECISION BIOSCIENCES INC: Amended and restated bylaws to address universal proxy rules, update stockholder nomination and proposal procedures, and make technical changes (effective 2023-12-19).
“On December 19, 2023, the Board of Directors (the “Board”) of Precision BioSciences, Inc. (the “Company”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.”
PRECISION BIOSCIENCES INC reported financial results for the third quarter ended September 30, 2023.
“On November 7, 2023, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.”
PRECISION BIOSCIENCES INC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).
“April 24, 2023, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). In response, the Company filed an application to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. As a result of the Approval, the Company has been granted an additional 180-day grace period, or until April 22, 2024, t”
PRECISION BIOSCIENCES INC amended Tenth Amendment to Lease Agreement with Venable Historic, LLC valued at annual base rent during the first period of the extension term of approximately $1.9 million (effective 2023-10-16).
“On October 16, 2023, Precision BioSciences, Inc. (the “Company”) and Venable Historic, LLC, successor-in-interest to Venable Tenant, LLC (the “Landlord”), entered into a Tenth Amendment to Lease Agreement (the “Lease Amendment”)”
PRECISION BIOSCIENCES INC amended Tenth Amendment to Lease Agreement with Venable Historic, LLC (effective 2023-10-16).
“On October 16, 2023, Precision BioSciences, Inc. (the “Company”) and Venable Historic, LLC (the “Landlord”) entered into a Tenth Amendment to Lease Agreement (the “Lease Amendment”)”
Alex Kelly changed role as Chief Financial Officer and Principal Accounting Officer at PRECISION BIOSCIENCES INC.
“On September 6, 2023, the Company’s Board of Directors designated Alex Kelly, the Company’s Chief Financial Officer and principal financial officer, to also serve as the Company’s principal accounting officer effective upon Mr. Barton’s departure.”
Shane Barton resigned as Vice President and Corporate Controller at PRECISION BIOSCIENCES INC.
“On August 31, 2023, Shane Barton notified Precision BioSciences, Inc. (the “Company”) of his resignation as the Company’s Vice President and Corporate Controller, effective September 15, 2023”
PRECISION BIOSCIENCES INC completed a disposition involving Imugene US for $8 million in cash and $13 million in convertible notes (closed 2023-08-15).
“are associated with the Company’s CAR T cell therapy business. In consideration for the Acquired Assets, Imugene US assumed certain liabilities of the Company, paid the Company $8 million in cash, and issued to the Company convertible notes in an aggregate principal amount of $13 million. The convertible notes are non-interest bearing and mature on the first”
PRECISION BIOSCIENCES INC entered into License Agreement with Imugene (USA) Inc. valued at $206 million (effective 2023-08-15).
“On the Closing Date, the Company and Imugene US entered into a License Agreement (the “License Agreement”), pursuant to which the Company granted Imugene US certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize oncological applications of the Company’s allogeneic CAR T therapy azer-cel and up to three additional research product candidates directed to targets that Imugene US may nominate prior to the fifth anniversary of the effective date of the License Agreement, pursuant to the terms of the License Agreement.”
PRECISION BIOSCIENCES INC entered into Asset Purchase Agreement with Imugene Limited and Imugene (USA) Inc. (collectively, Imugene) valued at $8 million (effective 2023-08-15).
“On August 15, 2023, Precision BioSciences, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Imugene Limited, an Australian corporation (“Imugene Limited”), and its wholly owned subsidiary Imugene (USA) Inc. (“Imugene US”), a Nevada corporation (collectively, “Imugene”).”
PRECISION BIOSCIENCES INC reported financial results for the quarter ended June 30, 2023.
“On August 4, 2023, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.”
PRECISION BIOSCIENCES INC amended A&R Development and License Agreement with Prevail Therapeutics Inc. valued at up to an aggregate of $390 million to $395 million per licensed product (effective 2023-06-30).
“On June 30, 2023, Precision BioSciences, Inc. (the “Company”) entered into an amended and restated development and license agreement (the “A&R Development and License Agreement”) with Prevail Therapeutics Inc. (“Prevail”), a wholly owned subsidiary of Eli Lilly and Company (“Lilly”).”
PRECISION BIOSCIENCES INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. at the 2023-05-04 meeting.
“Item 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 72,281,763 1,690,384 58,435 0”
PRECISION BIOSCIENCES INC shareholders approved Election of two Class I directors to serve until the Company's annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified. at the 2023-05-04 meeting.
“Item 1 – Election of two Class I directors to serve until the Company’s annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified. Votes FOR Votes WITHHELD Broker Non-Votes Michael Amoroso 40,370,180 12,559,294 21,101,108 Geno Germano 38,629,199 14,300,275 21,101,108”
PRECISION BIOSCIENCES INC reported financial results for the first quarter ended March 31, 2023.
“On May 9, 2023, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.”
PRECISION BIOSCIENCES INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“April 24, 2023, Precision BioSciences, Inc. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Co”
PRECISION BIOSCIENCES INC reported preliminary financial results for the quarter ended March 31, 2023.
“Although it has not finalized its full financial results for the quarter ended March 31, 2023, Precision BioSciences, Inc. (the “Company”) expects to report that it had approximately $158 million in cash and cash equivalents as of March 31, 2023.”
Derek Jantz changed role as Co-Founder and Chief Science Advisor at PRECISION BIOSCIENCES INC.
“On February 22, 2023, Derek Jantz, Ph.D. notified Precision BioSciences, Inc. (the “Company” or “Precision”) of his intentions to gradually step away from his current day-to-day responsibilities at Precision to pursue other personal and professional interests while continuing to support the Company’s external relationships, including with existing and potential business development partners.”
Raymond Schinazi resigned as Director at PRECISION BIOSCIENCES INC.
“On November 5, 2022, Dr. Raymond Schinazi informed the Board of Directors (the 'Board') of Precision BioSciences, Inc. (the 'Company' or 'Precision') that he was resigning from the Board, as well as his roles as Chair of the Board’s Nominating and Corporate Governance Committee and a member of the Board’s Compensation Committee and Science and Technology Committee, with immediate effect.”
PRECISION BIOSCIENCES INC reported financial results for the third quarter ended September 30, 2022.
“On November 8, 2022, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Derek Jantz resigned as Director at PRECISION BIOSCIENCES INC.
“Dr. Derek Jantz informed the Board of Directors (the "Board") that he was resigning from the Board with immediate effect”
Jeff Smith changed role as Chief Research Officer at PRECISION BIOSCIENCES INC.
“Jeff Smith, Ph.D., co-founder, will become Chief Research Officer reporting to the Chief Executive Officer from his prior role as Chief Technology Officer, with responsibility for management and direction of the Company’s research function.”
Melinda Brown was appointed as Class III Director and Chair of Audit Committee at PRECISION BIOSCIENCES INC.
“the Board of Directors (the “Board”) of Precision BioSciences, Inc. (the “Company”) appointed Melinda Brown to serve as a Class III director on the Company’s Board and as Chair of the Audit Committee of the Board.”
Shari Lisa Piré was appointed as Class III director at PRECISION BIOSCIENCES INC.
“Shari Lisa Piré to serve as a Class III director on the Company’s Board and as a member of the Nominating and Corporate Governance Committee of the Board”
Samuel Wadsworth was appointed as Class II director at PRECISION BIOSCIENCES INC.
“Samuel Wadsworth, Ph.D. to serve as a Class II director on the Company’s Board and as a member of the Science and Technology Committee of the Board”
Mathew Kane departed as President and Chief Executive Officer at PRECISION BIOSCIENCES INC.
“Mr. Amoroso succeeds Mathew Kane who, as previously reported, agreed to cease serving in both capacities effective with his successor’s commencement of service with the Company and to serve as a non-employee advisor to the Company through October 1, 2022”
Michael Amoroso was appointed as Director at PRECISION BIOSCIENCES INC.
“appointed Michael Amoroso to serve as President and Chief Executive Officer of the Company, as well as a member of the Board, in each case effective October 15, 2021”
Michael Amoroso was appointed as President and Chief Executive Officer at PRECISION BIOSCIENCES INC.
“appointed Michael Amoroso to serve as President and Chief Executive Officer of the Company, as well as a member of the Board, in each case effective October 15, 2021”
David Thomson resigned as Chief Operating Officer at PRECISION BIOSCIENCES INC.
“David Thomson, Ph.D., notified Precision BioSciences, Inc. (the “Company”) of his resignation as the Company’s Chief Operating Officer (“COO”), effective July 2, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.